Featured Research

from universities, journals, and other organizations

Breast cancer treatment selection improved by genomic tests

Date:
December 12, 2013
Source:
Thomas Jefferson University
Summary:
Genomic testing that determines the molecular subtype of a woman’s breast cancer provides a more precise prognosis and valuable guidance about the most effective avenue of treatment.

Genomic tests that determine the molecular subtype of a woman's breast cancer provide a more precise prognosis and valuable guidance about the best treatment, according to new research led by Massimo Cristofanilli, M.D, Director of the Jefferson Breast Care Center at the Kimmel Cancer Center (KCC) and Thomas Jefferson University and Hospitals.

Dr. Cristofanilli and colleagues concluded that the genomic tests MammaPrint® and BluePrint® from Agendia help oncologists better select the most effective therapy for individual patients. In a scientific poster presentation at the San Antonio Breast Cancer Symposium (SABCS), researchers reported that molecular subtyping is superior to traditional, clinical pathology methods at classifying the nature of a woman's breast cancer and more precisely tailoring each patient's treatment.

"We found that molecular subtyping is better than traditional methods for determining the exact biological nature of a woman's cancer and therefore what is the optimal course of treatment that will provide the best outcome for her," said Dr. Cristofanilli, a noted medical oncologist. "We are now using these genomic tests and molecular subtyping in our everyday clinical practice. One advantage of this approach is that we can better identify patients who would most benefit from chemotherapy, and also those who do not need to undergo chemotherapy."

Chemotherapy risks include immediate side effects, discomfort, and long-term damage. Several studies have concluded that chemotherapy provides no real benefit for many breast cancer patients because of their cancer subtype and low risk of recurrence.

Genomic testing is part of the revolution in personalized medicine. The tests examine the activity of groups of genes within a cancer tumor, to provide a more comprehensive view of the cancer and treatment options. The four subtypes are known as Luminal A, Luminal B, Basal-type and HER2-type.

The MammaPrint test predicts how likely it is that a woman's breast cancer will recur. BluePrint then identifies the molecular subtype of her cancer and predicts tumor response to targeted therapies before and after surgery.

Study details

Breast cancer tumors have traditionally been classified using immunochemistry (IHC) and fluorescent in-situ hybridization (FISH) techniques. Dr. Cristofanilli and colleagues compared the accuracy of IHC and FISH results to MammaPrint and BluePrint, which are part of the Symphony™ panel of genomic tests.

Researchers retrospectively analyzed 325 tumor samples from breast cancer patients whose age, survival and cancer pathology (IHC/FISH) findings were known. Median follow-up on those 325 patients was 10.2 years.

The statistically significant results showed that the genomic tests reclassified 25 percent of patients into different subtypes than the subtypes determined by IHC and FISH. By comparing patients' outcomes, researchers determined the overall superiority of the genomic tests over IHC and FISH.

MammaPrint and BluePrint more accurately predicted what is known as distant metastasis free survival (DMFS) at 5 years in patients with the various subtypes, including Luminal A-type (best outcome) and triple negative tumors (worse prognosis). BluePrint revealed a different molecular diagnosis than IHC and FISH in all four subtypes of breast cancer:

• 20 out of 208 (10%) diagnosed as luminal-like by IHC/FISH were reclassified as HER2-type (n=7) and as Basal-type (n=13)

• 26 out of 52 (50%) diagnosed as HER2 positive by IHC/FISH were reclassified as Luminal A (n=5), Luminal B (n=13), and Basal-type (n=8)

• 14 out of 65 (22%) diagnosed as triple negative by IHC/FISH were reclassified as Luminal A (n=2), Luminal B (n=5) and Basal-type (n=7)

The American Cancer Society estimates that in the U.S. in 2013, 232,340 women will be diagnosed with and 39,620 women will die of breast cancer.


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Cite This Page:

Thomas Jefferson University. "Breast cancer treatment selection improved by genomic tests." ScienceDaily. ScienceDaily, 12 December 2013. <www.sciencedaily.com/releases/2013/12/131212094926.htm>.
Thomas Jefferson University. (2013, December 12). Breast cancer treatment selection improved by genomic tests. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2013/12/131212094926.htm
Thomas Jefferson University. "Breast cancer treatment selection improved by genomic tests." ScienceDaily. www.sciencedaily.com/releases/2013/12/131212094926.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) — President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Obama Orders Military Response to Ebola

Obama Orders Military Response to Ebola

AP (Sep. 16, 2014) — Calling the Ebola outbreak in West Africa a potential threat to global security, President Barack Obama is ordering 3,000 U.S. military personnel to the stricken region amid worries that the outbreak is spiraling out of control. (Sept. 16) Video provided by AP
Powered by NewsLook.com
UN: 20,000 Could Be Infected With Ebola by Year End

UN: 20,000 Could Be Infected With Ebola by Year End

AFP (Sep. 16, 2014) — Nearly $1.0 billion dollars is needed to fight the Ebola outbreak raging in west Africa, the United Nations say, warning that 20,000 could be infected by year end. Duration: 00:40 Video provided by AFP
Powered by NewsLook.com
Obama: Ebola Outbreak Threat to Global Security

Obama: Ebola Outbreak Threat to Global Security

AP (Sep. 16, 2014) — President Obama is ordering U.S. military personnel to West Africa to deal with the Ebola outbreak, which is he calls a potential threat to global security. (Sept. 16) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

    Technology News



    Save/Print:
    Share:  

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile iPhone Android Web
    Follow Facebook Twitter Google+
    Subscribe RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins